Holen Sie sich die Stockscreener-App
27.67
2.22%
0.60
Vorhandelsmarkt:
28.23
0.56
+2.02%
Schlusskurs vom Vortag:
$27.07
Offen:
$26.9
24-Stunden-Volumen:
2.55M
Relative Volume:
0.64
Marktkapitalisierung:
$4.51B
Einnahmen:
$56.99M
Nettoeinkommen (Verlust:
$-107.23M
KGV:
-33.75
EPS:
-0.8199
Netto-Cashflow:
$-142.55M
1W Leistung:
+1.69%
1M Leistung:
-10.91%
6M Leistung:
+118.05%
1J Leistung:
+318.61%
1-Tages-Spanne:
$26.70
$28.09
1-Wochen-Bereich:
$26.70
$30.25
52-Wochen-Spanne:
$6.25
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
27.67 | 4.35B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
523.91 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.05 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
866.11 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.97 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.00 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-23 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Tango Therapeutics Inc (TNGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tango Therapeutics Inc (TNGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tango Therapeutics Inc (TNGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Tango Therapeutics Inc (TNGX) Cash Flow - TradingKey
Tango Therapeutics Inc (TNGX) Institutional Confidence - TradingKey
TNGX: Tango Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Tango Therapeutics, Inc. (TNGX) stock price, news, quote and history - Yahoo Finance UK
Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Tango Therapeutics Inc (TNGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Yahoo Finance Singapore
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
TNGX Maintained by Mizuho -- Price Target Raised to $40.00 - GuruFocus
Mizuho raises Tango Therapeutics stock price target on combo data - Investing.com
Mizuho raises Tango Therapeutics stock price target on combo data By Investing.com - Investing.com Nigeria
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.com - Investing.com Australia
JPMorgan initiates Tango Therapeutics stock at Overweight - Investing.com UK
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues - Yahoo Finance
TNGX Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
JPMorgan Initiates Coverage on Tango Therapeutics With Overweight Rating, $46 Price Target - marketscreener.com
J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46 - Moomoo
Tango Therapeutics Inc (TNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
2 Monster Growth Stocks Analysts Think Can Reach New Highs - The Globe and Mail
Does Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions? - simplywall.st
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com UK
Tango Therapeutics president Crystal Adam sells $798,908 in stock By Investing.com - Investing.com South Africa
Tango Therapeutics president Crystal Adam sells $798,908 in stock - Investing.com
Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares - Stock Titan
Price to book forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Tango Therapeutics Rides a New Precision Oncology Trend in 2026 - Yahoo Finance
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026? - Yahoo Finance
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts - Yahoo Finance
TNGX Q1 2026 Earnings: Net Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances PipelineHigh Growth Earnings - dars.gov.et
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $46 - GuruFocus
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark - marketscreener.com
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000E Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000E Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell Microcap Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tango Therapeutics Inc-Aktie (TNGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D |
Aug 03 '26 |
Sale |
27.24 |
27,000 |
735,517 |
115,743 |
0.82%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):